Equities

Supriya Lifescience Ltd

SUPRIYA:NSI

Supriya Lifescience Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)413.80
  • Today's Change11.95 / 2.97%
  • Shares traded1.72m
  • 1 Year change+89.12%
  • Beta--
Data delayed at least 15 minutes, as of Apr 25 2024 11:29 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Supriya Lifescience Limited is an India-based manufacturer of active pharmaceutical ingredients (APIs). The Company is primarily engaged in manufacturing of bulk drugs and pharmaceutical chemicals. The Company exports its products in the antihistamine, anesthetics and anti-asthma therapy categories to approximately 86 countries. The Company's product portfolio consists of approximately 38 niche API products that address remedies in therapeutic segments, such as antihistamine, analgesic, vitamin, anesthetics and anti-asthmatics, among others. The Company has manufacturing facilities located in Maharashtra. Its products include Chlorphenamine Maleate, Pheniramine Maleate, Brompheniramine Maleate, Dexchlorpheniramine Maleate, Mepyramine / Pyrilamine Maleate, Dexbrompheniramine Maleate, Cetirizine DiHCL, Diphenhydramine HCL, Bisoprolol Fumarate, Nicorandil, Mecobalamin, Hydroxocobalamin Sulphate, Hydroxocobalamin Acetate, and Hydroxocobalamin Hydrochloride, among others.

  • Revenue in INR (TTM)5.54bn
  • Net income in INR1.20bn
  • Incorporated2008
  • Employees392.00
  • Location
    Supriya Lifescience LtdSonawala Road Goregoan207/208, Udyog BhavanMUMBAI 400 063IndiaIND
  • Phone+91 2 240332727
  • Fax+91 2 226860011
  • Websitehttps://supriyalifescience.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Solara Active Pharma Sciences Ltd14.07bn-3.08bn19.86bn2.36k------1.41-85.65-85.65390.73--------5,958,916.00--2.68--4.1040.4744.49-21.884.58---1.67--10.1013.8322.6161.86--26.23--
Suven Life Sciences Ltd119.19m-1.06bn24.52bn132.00------205.75-5.20-5.200.5759--------902,939.40---31.29---35.32--66.93-890.87-127.02---744.27----14.31-53.543.06---41.37--
Jeena Sikho Lifecare Ltd-100.00bn-100.00bn25.40bn1.23k--80.33----------12.72------------------------0.8228--0.2681--43.84--77.37------
RPG Life Sciences Limited5.74bn847.70m25.50bn1.17k30.08--25.194.4551.2651.26346.80------------13.08--18.2668.1762.4214.789.71--296.86--29.2616.518.1231.3938.1316.1537.97
Morepen Laboratories Ltd16.31bn761.19m26.15bn1.65k33.89--24.451.601.511.5132.53--------9,891,111.00--7.39--13.7835.8532.824.675.19--27.34--0.00-8.3618.51-61.965.5011.33--
Innova Captab Ltd-100.00bn-100.00bn27.12bn--------------------------------------------------15.72--6.26------
Indoco Remedies Ltd17.96bn1.02bn30.33bn6.10k30.11--16.471.6910.9310.93192.26--------2,943,454.00--6.07--8.9069.3965.355.616.30--5.11--14.798.309.81-8.1128.158.2517.61
SeQuent Scientific Ltd13.75bn-1.29bn31.40bn478.00------2.28-5.18-5.1855.33--------28,769,920.00--2.33--3.6742.7842.47-8.972.59---0.3894--17.270.572810.84-395.83--12.88--
Gufic BioSciences Ltd7.85bn841.95m31.53bn1.63k36.47--29.894.028.628.6280.38--------4,820,074.00--12.30--23.0851.0844.9110.739.84--8.22--1.39-11.3617.47-16.8437.0686.8214.87
Supriya Lifescience Ltd5.54bn1.20bn32.38bn392.0026.87--23.935.8414.9714.9768.93--------14,144,410.00--20.77--29.0661.9455.8321.7224.33--63.63--2.02-13.0416.70-40.8159.4185.55--
Dishman Carbogen Amcis Ltd25.80bn-1.54bn36.60bn1.30k----24.841.42-9.84-9.84164.35--------19,919,850.00--0.4699--0.566576.9374.36-5.981.82---0.1245--202.7612.727.32-265.46--21.54--
Hikal Ltd18.16bn716.22m38.43bn2.14k53.70--20.922.125.805.80147.17--------8,477,077.00--5.86--8.8752.0845.413.946.37--2.78--10.144.139.25-51.160.297323.354.42
Unichem Laboratories Ltd16.75bn145.69m41.64bn3.12k286.23--31.952.492.072.07234.69--------5,364,373.00---1.38---1.6659.9456.150.8696-3.60---0.9613----5.7610.51-711.67---22.60--
Advanced Enzyme Technologies Ltd6.05bn1.37bn43.10bn338.0031.39--24.837.1312.2812.2854.16--------17,892,400.00--11.87--13.1976.4272.2023.0225.79--59.04--7.492.136.44-11.663.2428.3214.87
Data as of Apr 25 2024. Currency figures normalised to Supriya Lifescience Ltd's reporting currency: Indian Rupee INR

Institutional shareholders

5.91%Per cent of shares held by top holders
HolderShares% Held
Aditya Birla Sun Life Insurance Co. Ltd.as of 30 Jun 20232.94m3.65%
Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 30 Jun 20231.73m2.14%
Motilal Oswal Asset Management Co. Ltd.as of 31 Mar 202438.86k0.05%
SSgA Funds Management, Inc.as of 04 Apr 202436.73k0.05%
Dimensional Fund Advisors LPas of 04 Apr 20247.18k0.01%
Mellon Investments Corp.as of 04 Apr 20247.05k0.01%
Groww Asset Management Ltd.as of 31 Mar 2024173.000.00%
PineBridge Investments Asia Ltd.as of 30 Jun 20230.000.00%
More ▼
Data from 31 Dec 2023 - 18 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.